To date 640 teams from a possible 725 active transplants centers (88%) have reported to the 2019 activity survey. The finalized results will be published in the next annual report and be presented at EBMT 2021.
Within the rapidly developing field of cellular therapies, we are able to provide you with the preliminary numbers of CAR T cellular therapies reported to the activity survey in 2019 so far.
1079 CAR-T therapies (15 allogeneic and 1064 autologous) have been reported to the 2019 activity survey. This is an increase of 260%.
The indications for allogeneic CAR-T cellular therapy is ALL; 14 and other malignancy; 1. For autologous CAR-T, the indications are ALL; 266, lymphomas; 733, other malignancy; 64 and infection; 1.
The data stems from 110 centers in 19 countries, with the highest activity reported in France, Germany, Spain and the United Kingdom.